Is Laurus Labs (LAURUSLABS) overvalued or fairly valued?

MarketChacha shows Laurus Labs's valuation in context — a forward P/E of about 65.0, a price-to-book of about 15.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Laurus Labs's revenue?

Laurus Labs reported revenue of ₹6,089 Cr for FY2026, with net profit of ₹740 Cr, per official filings.

What is the share price of Laurus Labs (LAURUSLABS)?

Laurus Labs last traded at ₹1,578.00 (+1.2% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Laurus Labs

LAURUSLABS · NSE · Pharma · India

₹1,578.00+1.2%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:41 AM

Snapshot

TickerLAURUSLABS

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees7,059

HeadquartersHyderabad, India

Market cap₹84,220 Cr

P/B15.9

Volume6.75L

Websitewww.lauruslabs.com

Filings tracked0

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters32.0%
Institutions30.5%
Public & other37.4%

114 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

What's expected next

Next quarter

Rev ₹1,863 Cr · EPS 4.34

Est. earnings growth +20.2%

Next fiscal year

Rev ₹9,096 Cr · EPS 23.97

Est. earnings growth +18.8%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹810.0552-wk range₹1,590.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Quarterly · last 2

Market cap

₹84,220 Cr

Day change

+1.2%

Fwd P/E

65.0

P/B

15.9

Div yield

0.16%

Beta

0.43

Revenue (FY2026)

₹6,089 Cr

Net margin

12.2%

EPS (FY2026)

13.72

Net profit (FY2026)

₹740 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about LAURUSLABS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹6,089 Cr	₹740 Cr	13.72	12.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	₹1,580 Cr	₹192 Cr	3.55	12.1%
2025Q4	₹1,509 Cr	₹175 Cr	3.25	11.6%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.